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Table 1.0 Collection of autologous stem cells
Chemo-
mobilization
Cytokine
mobilization
p-value
Median CD34 cells/kg
collected (in millions/kg)
14.9 8.37 .009
Median number
of apheresis days (mean)
2
(2.13)
1
(1.76)
.29
Target dose achieved:
Yes
No
13 (81.3%)
3 (18.8%)
34 (91.9%)
3 (10%)
.26
Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127 S119median number of apheresis days was 1 (range 1 e 3). In 721
(88.7%) collections one day of apheresis was required to
achieve the minimum number of HPCs. The median apher-
esis volume for day 1 collections was 20 (range 3.6 e 24) L.
The correlation coefﬁcient between the pre-collection pe-
ripheral blood CD34+ cell count and the ﬁnal product CD34+
cell content is 0.69 (p<.001; Figure 1). The TVT estimate was
highly predictive of the ﬁnal product CD34+ count (r¼0.82,
p<.0001; Figure 2). Aminimumof 2 x 106 CD34+ cells/kgwas
collected in 90.4% of collections.
Discussion: Using the correlation between the pre-collec-
tion peripheral blood CD34+ count and the ﬁnal product HPC
content, the TVT formula can accurately determine the blood
volume to process during apheresis collection. This has
resulted in reduced apheresis time, fewer apheresis days, and
less nursing time. Ultimately, the TVT formula has allowed
our program to improve our resource utilization by accu-
rately predicating the required apheresis volume.155
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Background: Autologous stem cell mobilization can be
achieved using chemo-mobilization (CHM) or growth factors
alone (cytokine-mobilization, CTM). Mobilization with peg-
ﬁlgrastim and “just-in-time” plerixafor has been shown to be
a successful strategy. Experience with pegﬁlgrastim and
planned plerixafor is limited. We here describe our experi-
ence using two mobilization strategies with pegﬁlgrastim
plus plerixafor (CTM) or cyclophosphamide, pegﬁlgrastim
plus plerixafor (CHM).
Methods: We retrospectively identiﬁed patients who
received an auto-SCT for a diagnosis of myeloma at TJU be-
tween July 2010 and June 2013. These 53 patients who had
stem cell mobilization using either CHM (16 patients) with
cyclophosphamide (4 grams/m2), pegﬁlgrastim (12 mg) and
plerixafor (0.24 mg/kg once daily until target dose collected
or maximum of 4 days of apheresis), or CTM with pegﬁl-
grastim plus plerixafor (37 patients). Plerixafor was only
administered as an outpatient. We hypothesized that more
patients in the CHM group reached the prescribed total
CD34-positive stem cell collection as compared to the CTM
group. To test this hypothesis we used the two-sample test
on proportions. For the comparison of the median total CD34
cells/kg dose collection and the median number of apheresis
days we used the Wilcoxon rank sum test and the t-test,
respectively.
Results: There was no difference in patient age at transplant,
sex, and myeloma subtype. The median number of prior in-
duction therapies was similar; there was no signiﬁcant dif-
ference in the prior exposure to lenalidomide, however as
expected, bone marrow plasmacytosis was higher in theCHM group (6% vs. 2%). In the CHM group, 41% were hospi-
talized due to complication (typically neutropenic fevers)
and thus only 9 patients (59%) received the planned dose of
plerixafor as compared to 100% in the CTM group. Therewere
no hospitalizations in the CTM group due to toxicity. CHM
was associated with a signiﬁcantly higher median total
CD34+ cell collection (14.9 x 106/kg vs. 8.37 x 106/kg,
p¼0.009) (Table 2). CTM is associated with fewer collection
days (median 1 day vs. 2 days, p¼.29) and more patients
achieving the target CD34+ cell dose of 6.0 x 106/kg (91.9% vs.
81.3%, p¼.26).
Conclusion: The preferred method to mobilize autologous
stem cells should be with pegﬁlgrastim and planned plerix-
afor since it is able to achieve the prescribed cell dose, is
associated with less toxicity and risk of hospitalization. This
analysis suggests that per 100 patients collected a total of 100
days of plasmaphresis could be avoided if all patients were
mobilized with growth factors alone.156
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Background: Patients (pt) with advanced stage and high
International Prognostic Index (IPI) or relapsed/primary re-
fractory diffuse large B-cell lymphoma (DLBCL) have an
adverse prognosis and are frequently consolidated with
autologous stem cell transplantation (SCT).
Aim: Evaluation of a single center experience with SCT in
DLBCL.
Methods: Retrospective analysis of outcome of adult pt
submitted to SCT in DLBCL, between October 1992 and
December 2012. Data were collected from the database and
the medical records.
Results: 152 SCT were performed in various histological
subtypes of DLBCL, during this time period. Statistical anal-
ysis was performed in 113 pt with "classical" DLBCL and
histological variants were excluded.
Median age at SCT was 49 years (16-67), 68 males/45
females. At diagnosis the majority of pt were in advanced
stage (85%) and had an IPI 2 or 3 (47%, 30% respectively).
